Faktore meteorologikoen eta araknoide azpiko hemorragiaren agerpenaren arteko harremana

[EU] Laburpena: Lan honen helburu nagusia Donostiako ospitaleko pazienteetan faktore meteorologikoen eta berezko araknoide azpiko hemorragia aneurismatiko zein ez aneurismatikoaren/perimesentzefalikoaren artean harremanik dagoen aztertzea izan da. Aztertu diren faktore meteorologikoak tenperatura, presio atmosferikoa eta intsolazioa izan dira. Bestalde, faktore meteorologiko hauek hemorragia subaraknoideoaren larritasunarekin erlazionatzen diren ere ikertu nahi izan da. Azkenik, urtaroen arabera hemorragia subaraknoideoen kopurua aldatzen den ere ikusi nahi izan da. Hemorragia subaraknoidearen larritasunaren azterketan faktore meteorologikoez gain, HSA larritasunak sexuarekin, adinarekin, hipertentsioarekin eta erretzaile izatearekin harremana izan dezakeen ere aztertu nahi izan da. Ikerketa hau egiteko erabilitako diseinua atzera begirako behaketa kohorte ikerketa izan da, zehazki, 2016ko ekainetik 2020eko abendura bitartean HSA pairatu duten eta Donostiako ospitalean ingresatu diren pazienteen atzera begirako kohorte ikerketa. Emaitzek agerian utzi dute ikerketa gauzatu dugun eremu geografikoko faktore meteorologikoen artean eta Donostiako ospitalean HSAgatik ingresatu duten pazienteen artean, oro har ez dagoela harremanik. Hala ere, HSA motaren arabera sailkatzean, hau da, HSA aneurismatikoa eta HSA ez aneurismatikoa bakoitza bere aldetik aztertzean, HSA ez aneurismatikoa edo perimesentzefalikoa gertatu den egunetan bataz besteko presio atmosferikoaren balioa esanguratsuki altuagoa dela ikusi dugu. Bestalde, ez dugu urtaroen araberako ezberdintasunik ikusi HSA kopuruei dagokienez. Azkenik, larritasunari dagokionez ez da faktore meteorologikoen eta HSA aurkezpen larritasunaren artean desberdintasun esanguratsurik ikusi. Aitzitik, HSA aurkezpen larritasuna goran aipatutako barne aldagaiekin alderatzean, HSA larria izan duten pazienteetan erretzaileen ehunekoa nabarmenki handiagoa dela ikusi dugu. Lan honetatik hainbat ondorio eratortzen dira. Batetik, nahiz eta orokorrean faktore meteorologikoen eta HSA agerpenaren artean ez den erlazio argirik ikusi, HSA perimesentzefalikoa gertatu den egunetan presio atmosferiko altuagoa egon dela ikusi da. Honek bi HSA fisiopatologia desberdina izatearen teoria indartzeaz gain, abiarazle desberdinak izan ditzaketela pentsarazten gaitu eta honen inguruan gehiago ikertu beharko litzatekela proposatzera eramaten gaitu. Bestetik, nahiz eta faktore meteorologikoen eta HSA aurkezpen larritasunaren artean ez den harremanik agertu, argi ikusi dugu, HSA larria pairatu duten pazienteetan erretzaileen ehunekoa altuagoa dela. Beraz, gure ikerketan, alda dezakegun barne faktore batek aldaezinak diren kanpo faktoreek baino eragin handiagoa izan du HSA larritasunean. Honek erretzeari uzteko eskuhartzeak edo ohitura hori ekiditeko prebentzio programak martxan jartzearen garrantzia azpimarratzera garamatza

Local genetic variation of inflammatory bowel disease in Basque population and its effect in risk prediction

[EN] Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract. Although its aetiology remains unknown, environmental and genetic factors are involved in its development. Regarding genetics, more than 200 loci have been associated with IBD but the transferability of those signals to the Basque population living in Northern Spain, a population with distinctive genetic background, remains unknown. We have analysed 5,411,568 SNPs in 498 IBD cases and 935 controls from the Basque population. We found 33 suggestive loci (p 0.68. In conclusion, we report on the genetic architecture of IBD in the Basque population, and explore the performance of European-descent genetic risk scores in this population.Samples and data used in the present work were provided by the Basque Biobank (http://www.biobancovasco.org).We want to thank Miguel Angel Vesga from the Basque Centre of Transfusion and Human Tissues for providing the access to control samples. This work was founded to MD by Gipuzkoako Foru Aldundia/Diputacion Foral de Gipuzkoa. The project that gave rise to these results rece

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

Simple Summary An increased risk of hematological malignancies, mainly lymphomas, has been described in patients with inflammatory bowel disease (IBD). Because there are scarce data about the management and evolution of lymphomas in patients with IBD, the aim of our study was to analyze these points in those patients with IBD and lymphoma diagnosis included in the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD). We found that most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies. The five-year survival rate was 85% for non-Hodgkin lymphoma and 84% in patients with Hodgkin lymphoma. An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with IBD. IBD patients with diagnosis of lymphoma from October 2006 to June 2021 were identified from the prospectively maintained ENEIDA registry of GETECCU. We identified 52 patients (2.4 cases of lymphoma/1000 patients with IBD; 95% CI 1.8-3.1). Thirty-five were men (67%), 52% had ulcerative colitis, 60% received thiopurines, and 38% an anti-TNF drug before lymphoma diagnosis. Age at lymphoma was lower in those patients treated with thiopurines (53 +/- 17 years old) and anti-TNF drugs (47 +/- 17) than in those patients not treated with these drugs (63 +/- 12; p < 0.05). Five cases had relapse of lymphoma (1.7 cases/100 patient-years). Nine patients (17%) died after 19 months (IQR 0-48 months). Relapse and mortality were not related with the type of IBD or lymphoma, nor with thiopurines or biologic therapies. In conclusion, most IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these patients were younger at diagnosis of lymphoma than those not treated with these drugs. Relapse and mortality of lymphoma were not related with these therapies